Unraveling the therapeutic potential of the Hedgehog pathway in cancer
Top Cited Papers
- 7 November 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 19 (11), 1410-1422
- https://doi.org/10.1038/nm.3389
Abstract
Major progress has been made in recent years in the development of Hedgehog (Hh) pathway inhibitors for the treatment of patients with cancer. Promising clinical trial results have been obtained in cancers that harbor activating mutations of the Hh pathway, such as basal cell carcinoma and medulloblastoma. However, for many cancers, in which Hh ligand overexpression is thought to drive tumor growth, results have been disappointing. Here we review the preclinical data that continue to shape our understanding of the Hh pathway in tumorigenesis and the emerging clinical experience with smoothened inhibitors.This publication has 126 references indexed in Scilit:
- Loss of SUFU Function in Familial Multiple MeningiomaAmerican Journal of Human Genetics, 2012
- Dissecting the genomic complexity underlying medulloblastomaNature, 2012
- Medulloblastoma exome sequencing uncovers subtype-specific somatic mutationsNature, 2012
- The Crosstalk of mTOR/S6K1 and Hedgehog PathwaysCancer Cell, 2012
- Human colon cancer epithelial cells harbour active HEDGEHOG‐GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansionEMBO Molecular Medicine, 2009
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaNature, 2009
- A small molecule that binds Hedgehog and blocks its signaling in human cellsNature Chemical Biology, 2009
- Chapter 9 The Primary CiliumCurrent Topics in Developmental Biology, 2008
- HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and TumorigenicityCurrent Biology, 2007
- Mutations affecting segment number and polarity in DrosophilaNature, 1980